Rethinking prostate cancer screening: finding what matters
The Lancet Medical Imaging & Theranostics · 2026
DOI: 10.1016/j.lanmit.2026.100020 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Natasha Thorley und 3 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.
Abstract (Originalsprache)
Despite decades of research and widespread use of opportunistic prostate-specific antigen (PSA) testing, most countries have not implemented population-based prostate cancer screening programmes. Long-term follow-up of large-scale screening studies shows that interval PSA testing reduces mortality, but at the cost of overdiagnosis and overtreatment of disease that would never have caused harm.1 The question is, thus, not whether screening works—it does—but how to deliver the benefits of early detection without creating unacceptable harm.
Förderung
- National Institute for Health and Care Research
Zitieren
APA
Thorley, N., Atkinson, D., Emberton, M., & Punwani, S. (2026). Rethinking prostate cancer screening: finding what matters. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100020
Vancouver
Thorley N, Atkinson D, Emberton M, Punwani S. Rethinking prostate cancer screening: finding what matters. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100020
BibTeX
@article{Thorley2026,
author = {Thorley, Natasha and Atkinson, David and Emberton, Mark and Punwani, Shonit},
title = {Rethinking prostate cancer screening: finding what matters},
journal = {The Lancet Medical Imaging & Theranostics},
year = {2026},
doi = {10.1016/j.lanmit.2026.100020}
}
EUVIMED